MergerLinks Header Logo

Request Deal Involvement

Roivant Sciences went public via a SPAC merger with Montes Archimedes Acquisition in a $7.3bn deal.

Identify your role

Select the side you represented in this transaction, and provide your current job title.

Service Providers

TD Cowen

financial advisors

TD Cowen

Citigroup

financial advisors

Citigroup

JP Morgan

financial advisors

JP Morgan

Leerink Partners

financial advisors

Leerink Partners

Goldman Sachs

financial advisors

Goldman Sachs

Truist Securities

financial advisors

Truist Securities

Davis Polk & Wardwell

legal advisors

Davis Polk & Wardwell

Dukas Linden Public Relations

pr advisors

Dukas Linden Public Relations

White & Case

legal advisors

White & Case

Jefferies & Company

financial advisors

Jefferies & Company

Kirkland & Ellis

legal advisors

Kirkland & Ellis

Okapi Partners

pr advisors

Okapi Partners

Cooley

legal advisors

Cooley

or

Principals

ROIVANT SCIENCES LTD

target

ROIVANT SCIENCES LTD

MONTES ARCHIMEDES ACQUISITION CORP

bidder

MONTES ARCHIMEDES ACQUISITION CORP

PATIENT SQUARE CAPITAL

bidder

PATIENT SQUARE CAPITAL

FIDELITY MANAGEMENT & RESEARCH COMPANY

bidder

FIDELITY MANAGEMENT & RESEARCH COMPANY

EVENTIDE ASSET MANAGEMENT

bidder

EVENTIDE ASSET MANAGEMENT

SUVRETTA CAPITAL

bidder

SUVRETTA CAPITAL

RTW INVESTMENTS

bidder

RTW INVESTMENTS

VIKING GLOBAL INVESTORS

bidder

VIKING GLOBAL INVESTORS

SOFTBANK GROUP CORP

bidder

SOFTBANK GROUP CORP

SUMITOMO DAINIPPON PHARMA

bidder

SUMITOMO DAINIPPON PHARMA

PALANTIR TECHNOLOGIES

bidder

PALANTIR TECHNOLOGIES

Principals or Service Provider not listed?Add missing Service Provider or Principal

Enter your Job Title on this deal

This title will appear on your profile next to this deal involvement.


To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:

All rights reserved. Copyright © 2025 Datasite